JIP
LKFT

Jaffetilchin Investment Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Jaffetilchin Investment Partners’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$144 – 733
2024
Q3 		$144 Buy
+5
New +$136 ﹤0.01% 1328

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $8.43B AUM 52.02% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jaffetilchin Investment Partners's LKFT Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2024, closing a stake of 5 shares — an estimated $144 sold.

Jaffetilchin Investment Partners first reported a position in LKFT in Q3 2024 and held it in 1 quarter. The position peaked at $144 in Q3 2024. 81 funds tracked by Wall St. Rank hold LKFT as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 5 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2024, an estimated $144.
  • Jaffetilchin Investment Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $144 in Q3 2024.
  • 81 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.